Schwab Charles Investment Management Inc. Sells 10,743 Shares of Five Prime Therapeutics, Inc. (FPRX)

Schwab Charles Investment Management Inc. cut its stake in shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) by 8.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 111,797 shares of the biotechnology company’s stock after selling 10,743 shares during the quarter. Schwab Charles Investment Management Inc. owned approximately 0.40% of Five Prime Therapeutics worth $3,367,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Creative Planning lifted its holdings in Five Prime Therapeutics by 0.8% in the 2nd quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock worth $203,000 after purchasing an additional 54 shares in the last quarter. Bank of America Corp DE lifted its holdings in Five Prime Therapeutics by 5.8% in the 1st quarter. Bank of America Corp DE now owns 18,558 shares of the biotechnology company’s stock worth $671,000 after purchasing an additional 1,025 shares in the last quarter. American International Group Inc. lifted its holdings in Five Prime Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 16,614 shares of the biotechnology company’s stock worth $601,000 after purchasing an additional 1,100 shares in the last quarter. Weiss Multi Strategy Advisers LLC lifted its holdings in Five Prime Therapeutics by 7.1% in the 1st quarter. Weiss Multi Strategy Advisers LLC now owns 30,000 shares of the biotechnology company’s stock worth $1,085,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Essex Investment Management Co. LLC lifted its holdings in Five Prime Therapeutics by 22.2% in the 2nd quarter. Essex Investment Management Co. LLC now owns 12,692 shares of the biotechnology company’s stock worth $382,000 after purchasing an additional 2,308 shares in the last quarter. Institutional investors own 84.04% of the company’s stock.

FPRX has been the topic of a number of research analyst reports. Jefferies Group LLC reissued a “buy” rating and issued a $52.00 price target (down from $55.00) on shares of Five Prime Therapeutics in a report on Thursday, August 10th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $41.00 price objective on shares of Five Prime Therapeutics in a report on Wednesday. Zacks Investment Research raised Five Prime Therapeutics from a “sell” rating to a “buy” rating and set a $49.00 price objective on the stock in a report on Monday, October 16th. BMO Capital Markets reissued a “hold” rating and set a $39.00 target price on shares of Five Prime Therapeutics in a research report on Friday, September 22nd. Finally, ValuEngine raised Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $54.83.

TRADEMARK VIOLATION NOTICE: This article was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.dispatchtribunal.com/2017/10/28/five-prime-therapeutics-inc-fprx-stake-lowered-by-schwab-charles-investment-management-inc.html.

Five Prime Therapeutics, Inc. (NASDAQ FPRX) opened at 45.94 on Friday. The company’s market cap is $1.29 billion. Five Prime Therapeutics, Inc. has a 12 month low of $25.97 and a 12 month high of $60.98. The firm has a 50-day moving average price of $39.15 and a 200 day moving average price of $32.65.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.15) by ($0.43). The firm had revenue of $7.80 million during the quarter, compared to analyst estimates of $8.32 million. Five Prime Therapeutics had a negative return on equity of 31.78% and a negative net margin of 356.39%. The firm’s revenue for the quarter was down 16.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.49) earnings per share. Equities research analysts predict that Five Prime Therapeutics, Inc. will post ($5.29) EPS for the current year.

In other Five Prime Therapeutics news, Director William R. Ringo sold 1,800 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $40.26, for a total value of $72,468.00. Following the transaction, the director now owns 1,200 shares of the company’s stock, valued at $48,312. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William R. Ringo sold 2,000 shares of the firm’s stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $38.00, for a total transaction of $76,000.00. Following the completion of the transaction, the director now directly owns 2,000 shares in the company, valued at approximately $76,000. The disclosure for this sale can be found here. 6.50% of the stock is currently owned by company insiders.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply